Index of reports
> Cases with Thrombocytopenia (100)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Velcade (Bortezomib) where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 100 Next >>
Possible Velcade side effects in male
Reported by a physician from Germany on 2012-08-24
Patient: male
Reactions: Portal Hypertension, Pain, Thrombocytopenia, Epistaxis, Decreased Appetite, Renal Failure Acute, Bronchopulmonary Aspergillosis, Pseudomonas Infection, Anaemia, Hyperviscosity Syndrome, Rash, Haemangioma of Spleen, Pulmonary Sepsis, Syncope, Respiratory Failure, Visual Impairment, Leukopenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cotrim DS
Indication: Product Used FOR Unknown Indication
Dexamethasone Sodium Phosphate
Indication: Multiple Myeloma
Start date: 2012-03-21
End date: 2012-04-01
Dexamethasone Sodium Phosphate
Start date: 2012-03-01
End date: 2012-03-12
Dexamethasone Sodium Phosphate
Start date: 2012-05-21
End date: 2012-06-10
Dexamethasone Sodium Phosphate
Start date: 2012-04-17
End date: 2012-04-28
Doxorubicin HCL
Indication: Multiple Myeloma
Start date: 2012-03-21
End date: 2012-04-01
Doxorubicin HCL
Start date: 2012-04-17
End date: 2012-04-28
Lenalidomide
Indication: Multiple Myeloma
Start date: 2012-05-21
End date: 2012-06-10
Velcade
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-28
Velcade
Start date: 2012-03-21
End date: 2012-04-01
Velcade
Start date: 2012-03-01
End date: 2012-03-12
Other drugs received by patient: Acyclovir
Possible Velcade side effects in
Reported by a physician from France on 2012-08-23
Patient:
Reactions: Back Pain, Electrocardiogram QT Prolonged, Dyspnoea, Hypotension, Thrombocytopenia
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-22
End date: 2012-05-29
JNJ-26481585
Dosage: 12 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-21
End date: 2012-05-31
Velcade
Dosage: 2.1 mg, unk
Indication: Multiple Myeloma
Start date: 2012-05-22
End date: 2012-05-29
Other drugs received by patient: Ceftriaxone; Primperan / 00041901 /; Acetaminophen; Zelitrex / 01269701 /; Fentanyl; Atracurium Besylate; Kardegic / 00002703 /; Oxycontin; Oxygen; Tranxene; Primperan / 00041901 /; Bumetanide; Crestor; Primperan / 00041901 /; Hydrocortisone; Ondansetron; Ondansetron; Ondansetron; Importal; Tramadol HCL; Noradrenaline / 00127501 /; Tramadol HCL; Morphine; Furosemide; Midazolam; Tramadol HCL
Possible Velcade side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22
Patient: male, weighing 86.2 kg (189.6 pounds)
Reactions: Vomiting, Nausea, Hypotension, Systemic Inflammatory Response Syndrome, Pyrexia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in 70 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22
Patient: 70 year old male, weighing 104.3 kg (229.5 pounds)
Reactions: Pneumonia, Thrombocytopenia, Groin Pain
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Torisel
Dosage: 25 mg d1, d8 iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2012-07-30
End date: 2012-08-06
Velcade
Dosage: 3.6 mg d1, d8 iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2012-07-30
End date: 2012-08-06
Possible Velcade side effects in
Reported by a physician from France on 2012-08-21
Patient:
Reactions: Overdose, Thrombocytopenia
Drug(s) suspected as cause:
Dexamethasone
Dosage: 10 mg, unk
Indication: Multiple Myeloma
Start date: 2012-01-23
End date: 2012-08-03
Revlimid
Dosage: 25 mg, unk
Indication: Multiple Myeloma
Start date: 2012-01-23
End date: 2012-08-05
Velcade
Dosage: unk mg, unk
Indication: Multiple Myeloma
Start date: 2012-01-23
Velcade
Dosage: 1 unk, unk
Start date: 2012-03-01
End date: 2012-08-02
Other drugs received by patient: Amoxicillin; Innohep; Morphine Sulfate; Nexium; Xatral / 00975301 /; Potassium Chloride; Bactrim; Lexomil
Possible Velcade side effects in
Reported by a physician from Greece on 2012-08-21
Patient:
Reactions: Thrombocytopenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Velcade
Possible Velcade side effects in
Reported by a physician from Turkey on 2012-08-20
Patient:
Reactions: Pneumonia, Thrombocytopenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2009-02-09
End date: 2009-04-20
Velcade
Dosage: 2.57 mg, unk
Indication: Multiple Myeloma
Start date: 2009-02-09
End date: 2009-04-20
Possible Velcade side effects in
Reported by a physician from Italy on 2012-08-20
Patient:
Reactions: Dyspnoea, Anaemia, Pancytopenia, Thrombocytopenia, Asthenia
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Velcade
Other drugs received by patient: Nitroglycerin; Bisoprolol Fumarate; Dexamethasone; Furosemide; Lasix; Dexamethasone
Possible Velcade side effects in
Reported by a physician from United States on 2012-08-17
Patient:
Reactions: Vomiting, Cardio-Respiratory Arrest, International Normalised Ratio Increased, Thrombocytopenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-07-03
End date: 2012-07-14
Velcade
Dosage: 1.3 mg, unk
Indication: Multiple Myeloma
Start date: 2012-07-03
End date: 2012-07-13
Other drugs received by patient: Carvedilol; Omeprazole; Calcium; Acenocoumarol; Candesartan Cilexetil; Prednisone TAB; Furosemide; Folic Acid; Movicol / 01053601 /
Possible Velcade side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Velcade side effects in
Reported by a physician from France on 2012-08-16
Patient:
Reactions: Electrocardiogram QT Prolonged, Back Pain, Dyspnoea, Hypotension, Thrombocytopenia
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-22
End date: 2012-05-29
JNJ-26481585
Dosage: 12 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-21
End date: 2012-05-31
Velcade
Dosage: 2.1 mg, unk
Indication: Multiple Myeloma
Start date: 2012-05-22
End date: 2012-05-29
Other drugs received by patient: Ceftriaxone; Primperan / 00041901 /; Bumetanide; Acetaminophen; Morphine; Atracurium Besylate; Ondansetron; Crestor; Fentanyl; Furosemide; Midazolam; Tranxene; Ondansetron; Tramadol HCL; Noradrenaline / 00127501 /; Hydrocortisone; Importal; Tramadol HCL; Kardegic / 00002703 /; Primperan / 00041901 /; Primperan / 00041901 /; Tramadol HCL; Zelitrex / 01269701 /; Oxycontin; Oxygen; Ondansetron
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-10
Patient:
Reactions: Off Label Use, Chest Pain, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Other drugs received by patient: Oxazepam; Acebutolol; Ramipril; Kardegic / 00002703 /; Zolpidem; Flecainide Acetate; Dafalgan / 00020001 /
Possible Velcade side effects in
Reported by a physician from Netherlands on 2012-08-07
Patient:
Reactions: Diabetes Mellitus, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Dexamethasone
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Velcade
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Other drugs received by patient: Omeprazole; Fluconazole; Zelitrex / 01269701 /; Ciproxin / 00697201 /; Metoclopramide
Possible Velcade side effects in male
Reported by a physician from Germany on 2012-08-07
Patient: male
Reactions: Portal Hypertension, Pain, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Epistaxis, Bronchopulmonary Aspergillosis, Pseudomonas Infection, Anaemia, Hyperviscosity Syndrome, Rash, Pulmonary Sepsis, Haemangioma of Spleen, Syncope, Respiratory Failure, Visual Impairment, Leukopenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cotrim DS
Indication: Product Used FOR Unknown Indication
Dexamethasone Sodium Phosphate
Start date: 2012-05-21
End date: 2012-06-10
Dexamethasone Sodium Phosphate
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-28
Dexamethasone Sodium Phosphate
Start date: 2012-03-01
End date: 2012-03-12
Dexamethasone Sodium Phosphate
Start date: 2012-03-21
End date: 2012-04-01
Doxorubicin HCL
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-28
Doxorubicin HCL
Start date: 2012-03-21
End date: 2012-04-01
Lenalidomide
Indication: Multiple Myeloma
Start date: 2012-05-21
End date: 2012-06-10
Velcade
Indication: Multiple Myeloma
Start date: 2012-03-01
End date: 2012-03-12
Velcade
Start date: 2012-04-17
End date: 2012-04-28
Velcade
Start date: 2012-03-21
End date: 2012-04-01
Other drugs received by patient: Acyclovir
Possible Velcade side effects in
Reported by a physician from Japan on 2012-08-06
Patient:
Reactions: Disseminated Intravascular Coagulation, Neutropenia, Gastric Ulcer, Thrombocytopenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Melphalan Hydrochloride
Dosage: 8 mg, unk
Indication: Multiple Myeloma
Start date: 2012-04-24
End date: 2012-04-28
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Multiple Myeloma
Start date: 2012-03-29
End date: 2012-06-21
Other drugs received by patient: Zometa; Prednisolone; Loxoprofen; Dexamethasone
Possible Velcade side effects in male
Reported by a physician from Germany on 2012-08-06
Patient: male
Reactions: Portal Hypertension, Pain, Thrombocytopenia, Epistaxis, Decreased Appetite, Renal Failure Acute, Bronchopulmonary Aspergillosis, Anaemia, Pseudomonas Infection, Hyperviscosity Syndrome, Rash, Pulmonary Sepsis, Haemangioma of Spleen, Syncope, Respiratory Failure, Visual Impairment, Leukopenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cotrim DS
Indication: Product Used FOR Unknown Indication
Dexamethasone Sodium Phosphate
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-28
Dexamethasone Sodium Phosphate
Start date: 2012-03-21
End date: 2012-04-01
Dexamethasone Sodium Phosphate
Start date: 2012-05-21
End date: 2012-06-10
Dexamethasone Sodium Phosphate
Start date: 2012-03-01
End date: 2012-03-12
Doxorubicin HCL
Start date: 2012-03-21
End date: 2012-04-01
Doxorubicin HCL
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-28
Lenalidomide
Indication: Multiple Myeloma
Start date: 2012-05-21
End date: 2012-06-10
Velcade
Indication: Multiple Myeloma
Start date: 2012-03-01
End date: 2012-03-12
Velcade
Start date: 2012-04-17
End date: 2012-04-28
Velcade
Start date: 2012-03-21
End date: 2012-04-01
Other drugs received by patient: Acyclovir
Possible Velcade side effects in
Reported by a physician from Korea, Republic of on 2012-08-02
Patient:
Reactions: Pneumonia, Neutropenia, Thrombocytopenia, Septic Shock
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Melphalan Hydrochloride
Dosage: 18 mg/m2, unk
Indication: Multiple Myeloma
Start date: 2012-01-27
End date: 2012-01-30
Melphalan Hydrochloride
Dosage: 11 mg/m2, unk
Start date: 2012-03-22
End date: 2012-03-25
Prednisolone
Dosage: 58 mg/m2, unk
Indication: Multiple Myeloma
Start date: 2012-01-27
End date: 2012-01-30
Velcade
Dosage: 1.3 mg/m2, unk
Indication: Multiple Myeloma
Start date: 2012-01-27
End date: 2012-04-01
Possible Velcade side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-31
Patient:
Reactions: Mantle Cell Lymphoma Refractory, Skin Toxicity, Neurotoxicity, Neuropathy Peripheral, Hepatotoxicity, Cardiotoxicity, Thrombocytopenia, Renal Disorder, Drug Effect Decreased, Gastrointestinal Toxicity, Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Mantle Cell Lymphoma, Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Chlorambucil
Dosage: from day 20 to 29.
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: day 1 to 4
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: as a continuous infusion from day 1 to 4
Doxorubicin Hydrochloride
Dosage: as a continuous infusion from day 1 to 4
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: on day 1 (and day 8 of cycle 1)
Indication: Mantle Cell Lymphoma
Velcade
Dosage: on days 1, 4, 8 and 11
Indication: Mantle Cell Lymphoma
Possible Velcade side effects in
Reported by a physician from Japan on 2012-07-23
Patient:
Reactions: Pneumonia, C-Reactive Protein Increased, Dehydration, Atrial Fibrillation, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-03-12
Panobinostat
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-03-12
Velcade
Dosage: 2.3 mg, unk
Indication: Multiple Myeloma
Start date: 2012-03-12
Other drugs received by patient: Amlodipine; Candesartan Cilexetil; Mucosta; Warfarin Sodium
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-19
Patient:
Reactions: Mantle Cell Lymphoma Refractory, Skin Toxicity, Neurotoxicity, Neuropathy Peripheral, Hepatotoxicity, Cardiotoxicity, Thrombocytopenia, Drug Effect Decreased, Renal Disorder, Gastrointestinal Toxicity, Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Mantle Cell Lymphoma, Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Chlorambucil
Dosage: from day 20 to 29.
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: day 1 to 4
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: as a continuous infusion from day 1 to 4
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: on day 1 (and day 8 of cycle 1)
Indication: Mantle Cell Lymphoma
Velcade
Dosage: on days 1, 4, 8 and 11
Indication: Mantle Cell Lymphoma
Possible Velcade side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient:
Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 milligram/sq. meter
Indication: Multiple Myeloma
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Revlimid
Dosage: 15 milligram
Administration route: Oral
Velcade
Dosage: 1.3 milligram/sq. meter
Indication: Multiple Myeloma
Velcade
Dosage: 1.3 milligram/sq. meter
Possible Velcade side effects in
Reported by a physician from Japan on 2012-07-17
Patient:
Reactions: Pneumonia, Pain, Atrial Fibrillation, Interstitial Lung Disease, C-Reactive Protein Increased, Dehydration, Dizziness, Thrombocytopenia, Decreased Appetite, Infection Susceptibility Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-03-12
Panobinostat
Dosage: 20 mg, unk
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-03-12
Velcade
Dosage: 2.3 mg, unk
Indication: Multiple Myeloma
Start date: 2012-03-12
Other drugs received by patient: Amlodipine; Candesartan Cilexetil; Warfarin Sodium; Mucosta
Possible Velcade side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-16
Patient: male, weighing 86.2 kg (189.6 pounds)
Reactions: Vomiting, Nausea, Hypotension, Systemic Inflammatory Response Syndrome, Pyrexia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Multiple Myeloma
Start date: 2012-04-17
End date: 2012-04-24
Velcade
Dosage: 2.3 mg, unk
Start date: 2012-05-04
Possible Velcade side effects in
Reported by a physician from Japan on 2012-07-12
Patient:
Reactions: Disseminated Intravascular Coagulation, Neutropenia, Gastric Ulcer, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Other drugs received by patient: Melphalan Hydrochloride; Zometa; Loxoprofen; Prednisolone; Dexamethasone
Possible Velcade side effects in 61 year old female
Reported by a physician from United States on 2012-07-11
Patient: 61 year old female, weighing 61.4 kg (135.1 pounds)
Reactions: Anaemia, Chills, Febrile Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: day of and after velcade
Indication: Multiple Myeloma
Start date: 2012-07-02
End date: 2012-07-03
Revlimid
Dosage: days 1-14
Indication: Multiple Myeloma
Start date: 2012-07-02
End date: 2012-07-03
Velcade
Dosage: days 1, 4, 8, 11
Indication: Multiple Myeloma
Start date: 2012-07-02
End date: 2012-07-02
Other drugs received by patient: Prilosec; Lovenox; Acyclovir
Possible Velcade side effects in
Reported by a consumer/non-health professional from United States on 2012-07-09
Patient:
Reactions: Dyspnoea, Anaemia, General Physical Health Deterioration, Oesophageal Haemorrhage, Thrombocytopenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 8 mg, cyclic
Indication: Multiple Myeloma
Start date: 2010-08-30
End date: 2011-11-04
Doxorubicin HCL
Dosage: 9 mg/m2, cyclic
Indication: Multiple Myeloma
Start date: 2011-08-30
End date: 2011-11-04
Velcade
Dosage: 1.3 mg, cyclic
Indication: Multiple Myeloma
Start date: 2011-08-30
End date: 2011-11-04
Other drugs received by patient: Moxonidin; Amlodipine; Finasterid Orion; Metoprolol Tartrate; Ramipril; Allopurinol; Levothyroxine Sodium; Calcivit D; Pantozol / 01263202 /; Hydromorphone HCL; Decostriol; Prednisone TAB; Tamsulosin HCL; Torsemide; Folsan
Possible Velcade side effects in
Reported by a pharmacist from Netherlands on 2012-07-06
Patient:
Reactions: Diarrhoea, Oliguria, Colitis, Pyrexia, Thrombocytopenia, Leukopenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Velcade
Other drugs received by patient: Valaciclovir; Cyclophosphamide; Fluconazole; Cotrim; Dexamethasone
Possible Velcade side effects in male
Reported by a pharmacist from Netherlands on 2012-07-06
Patient: male, weighing 80.0 kg (176.0 pounds)
Reactions: Colitis, Thrombocytopenia, Leukopenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2012-05-04
Velcade
Indication: Multiple Myeloma
Start date: 2012-05-04
Other drugs received by patient: Fluconazole; Valaciclovir; Dexamethasone; Cotrim
Possible Velcade side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Velcade
Dosage: on days 1 and 8
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Page 1 Next >>
|